The Leucegene team is dedicated to provide:

  • Improved AML stratification and AML prognostic tests
  • Minimal residual disease tests
  • Targeted AML treatments either through novel lead compound development or repurposed drugs
  • Socio-economic analysis and ethico-legal recommendations to facilitate adoption of change